-+ 0.00%
-+ 0.00%
-+ 0.00%

Lundbeck says FDA grants Fast Track status to narcolepsy drug candidate Lu AH69593

PUBT·07/23/2026 07:01:07
Listen to the news
Lundbeck says FDA grants Fast Track status to narcolepsy drug candidate Lu AH69593
  • H. Lundbeck received FDA Fast Track designation for Lu AH69593, an oral orexin 2 receptor agonist for narcolepsy.
  • Lu AH69593 is in Phase 1b development, positioning the program for closer FDA interaction and a potentially faster review path.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H. Lundbeck A/S published the original content used to generate this news brief via Cision (Ref. ID: 202607230300BITN____UKPR__EN_20260722-BIT-1039-0) on July 23, 2026, and is solely responsible for the information contained therein.